ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 226 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $88 | -78.8% | 1,940 | -81.4% | 0.00% | -100.0% |
Q1 2023 | $416 | +82.5% | 10,403 | +109.5% | 0.00% | +100.0% |
Q4 2022 | $228 | -99.3% | 4,966 | +544.9% | 0.00% | – |
Q3 2022 | $31,000 | -22.5% | 770 | +81.6% | 0.00% | – |
Q2 2021 | $40,000 | -20.0% | 424 | +16.5% | 0.00% | – |
Q4 2020 | $50,000 | – | 364 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |